VIVEbiotech makes a capital increase of 3.5 million euros to complete its expansion plan
VIVEbiotech has carried out a capital increase of 3.5 million euros to finance its strategic plan, which highlights the construction of three new cleanrooms and the incorporation of new equipment that will multiply its production capacity substantially. VIVEbiotech will now have 600 square meters of clean rooms with 8 nanobioreactors and two large capacity bioreactors.
Thanks to this growth, in 2021 VIVEbiotech will be able to produce lentiviral vectors for advanced clinical trials in which hundreds of patients participate, as well as to attend the commercial scale production of any gene therapy product that uses lentivirus. The trend of the gene therapy market is growing and with the new infrastructure VIVEbiotech will be able to respond to this reality.
The capital increase has been endorsed by VIVEbiotech´s private partners who continue with their commitment to the company and its future. Easo Ventures and Inveready are the new shareholders, the latter being a venture capital fund with extensive experience in biotechnology.
VIVEbiotech is already producing lentiviral vectors for 16 gene therapy projects, 6 of them with CAR-Ts. Customers are located in European countries, the United States, Israel and Australia.
Related news
CIC biomaGUNE launches a company that will transform disease diagnosis by using nanosensors
Taldeki Biosolutions will be developing sensors for rapid, cost-effective, robust antibody detection, thus overcoming the stability and cost problems of current in vitro diagnostics
VIVEbiotech Secures Growth Investment from Ampersand Capital Partners to Expand Lentiviral Vector Development and Manufacturing Capabilities
Support the execution of a robust pipeline of customer projects for innovators developing groundbreaking in vivo and ex vivo cell and gene therapies.
CIC nanoGUNE launches a new call: Industry Collaborative Research Positions
Programa honen helburua da ikertzaile profesionalak tokiko erakundeetan sar daitezen erraztea
Companies with greater gender equality perform better in terms of innovation and are more competitive
The study of the SPRI initiative "Women in Industry" shows that gender equality has an impact on the improvement of company results.
SPRI presents the results of the study on the impact of women on industrial competitiveness at the World Manufacturing Forum
The reports is the continuation of the work carried out by the SPRI Group and the Foreign Network office in Milan since 2020 as leader of the Women in Manufacturing expert group.